drugset / Trial / NCT03932825

Nitrous Oxide for Major Depressive Disorder

NCT03932825

Phase 2 Completed 44 enrolled Lingjiang Li
RandomizedParallel-groupDouble-blindTreatment

Summary

This study aims at investigating the persistence of antidepressant effect of Nitrous Oxide (N2O) for Treatment-Resistant Depression(TRD). The investigators also aim to assess the effect of N2O on the electroencephalograph, multimodal magnetic resonance imaging(MRI), blood cytokines, feces bacteria flora and neuropsychological performance in patients with TRD. The investigators further aim to identify the predictors of N2O's antidepressant effeect using the above techniques.

Timeline

Start
2019-04-01
Primary completion
2021-03-31
Completion
2021-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Nitrous Oxide Other / unclassified 50 % Inhaled